FY2025 full-year results are sales of 62 billion yen, operating income of 1.47 billion yen, and net income of -0.2 billion yen. The mid-term management plan for FY2026\u20132027 has been revised, setting a goal of 65 billion yen in sales and 2.5 billion yen in operating income.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"5988","jir_company_name":"Piaolax Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/5988-20260512-04.pdf","jir_short_summary":"FY2025 full-year results are sales of 62 billion yen, operating income of 1.47 billion yen, and net income of -0.2 billion yen. The mid-term management plan for FY2026\u20132027 has been revised, setting a goal of 65 billion yen in sales and 2.5 billion yen in operating income.","jir_summary":"### FY2025 Full-year Performance Review\nFY2025 full-year actuals include sales of 62 billion yen, operating income of 1.47 billion yen, operating profit margin of 2.4%, and net income of -0.2 billion yen. Compared to the same period last year, there was a decline in revenue and profit, pressured by significant reductions in OEM production volumes, increased variable costs, and one-time losses recorded by overseas subsidiaries. While recovery from the COVID-19 pandemic is underway, low production volumes in key OEM customers and rising costs due to inflation have contributed to the deterioration of operating profit.\n\n### Revision of Mid-term Management Plan and Future Strategy\nThe FY2025\u20132027 mid-term management plan has been revised, setting targets of 65 billion yen in sales and 2.5 billion yen in operating income for FY2027. After the structural reform phase (2025\u20132027), the company will gradually restore profitability toward an expansion phase and a sustainable growth phase beyond 2030. Key strategies include diversification with OEM partners, expansion across global markets, growth investments in the medical device business, improving breakeven points, strengthening product strategies (ADAS-related, electrification-compatible products), and regional strategic development. Particular focus will be on restructuring earnings in Japan, North America, and China, aiming for an early achievement of an ROE above 8%.","jir_financial_highlights":"Sales: 620 billion yen (Decreased from FY2024 actual of 633 billion yen)\nOperating Income: 14.7 billion yen (Decreased from FY2024 actual of 23.8 billion yen)\nOperating Profit Margin: 2.4% (Decreased from FY2024 actual of 3.8%)\nNet Income: -0.2 billion yen (Significantly decreased from FY2024 actual of 17.9 billion yen)\nFY2027 Sales Target: 650 billion yen (Decreased from previous target of 690 billion yen)\nFY2027 Operating Income Target: 2.5 billion yen (Significantly decreased from previous 6.3 billion yen)","jir_category":"","jir_hashtags":"#PiaolaxCorporation, #MidTermManagementPlan, #BusinessStrategy","jir_key_figures":"FY2025 Sales: 620 billion yen (YoY decrease)\nFY2025 Operating Income: 14.7 billion yen (YoY decrease)\nFY2027 Sales Target: 650 billion yen (revised from previous 690 billion yen)","jir_meta_title":"\u3010Piaolax Corporation\u3011Revision of Mid-term Management Plan\uff5cFY2027 Sales Target Revised to 650 billion yen","jir_meta_description":"Piaolax Corporation announced a revision of its mid-term management plan in May 2026. FY2025 full-year sales were 62 billion yen, with an operating income of 14.7 billion yen. The FY2027 sales target has been revised to 650 billion yen, aiming for profitability recovery.","jir_og_title":"\u3010Piaolax Corporation\u3011Revision of Mid-term Management Plan\uff5cFY2027 Sales Target of 650 billion yen","jir_og_description":"Announcement of FY2025 full-year results and revisions to the mid-term management plan. Sales of 62 billion yen, operating income of 14.7 billion yen. Outlines growth strategies toward FY2027.","jir_og_image_url":"\/assets\/og\/company-business_update.jpg","jir_chart_data_collection":"[]","ir_related_company":17092,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-48407","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n